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Dual antiplatelet therapy based on the combination of an adenosine diphosphate (ADP)-receptor antagonist plus
aspirin has demonstrated to be more effective in reducing the rate of major ischemic vascular events compared to
aspirin monotherapy in some clinical settings. The current controversy on the duration of dual antiplatelet therapy
should not conceal another major issue: the choice of the more appropriate antiplatelet monotherapy after the dual
treatment phase. The aim of this article is to critically analyze the available evidence in this topic.
Data from studies like CAPRIE, MATCH, PROFESS, CHANCE, DAPT and others, raise questions as why antiplatelet
monotherapy after the dual phase should only be based on aspirin, in spite of a lack of evidence surprisingly not
highlighted by key opinion leaders and experts.
We conclude that, whether ADP-receptor antagonist rather than aspirin may be proposed as monotherapy seems
not only have no answer but also not place in the current specialists’ analysis, as if a dogmatic approach were
prevalent. Perhaps the time for an open debate on these topics is ripe.
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At the end of the 90s dual antiplatelet therapy based on
the combination of an ADP-receptor antagonist plus as-
pirin has been proposed to reach a more efficient inhib-
ition of platelet function by simultaneously blocking
different platelet-activation pathways [1]. This approach
demonstrated to be more effective in reducing the rate
of major ischemic vascular events compared to aspirin
monotherapy, but only in some clinical settings. For in-
stance, in coronary artery disease (CAD), dual antiplate-
let therapy with aspirin plus clopidogrel has long been
considered the standard of care for treating acute coron-
ary syndrome (ACS) and after percutaneous coronary
intervention (PCI) since its benefits over aspirin mono-
therapy has been well established [2–7]. In patients with
acute ischemic stroke and in subjects with symptomatic
peripheral arterial disease (PAD), even recent guidelines
did not recommend (or did it only for selected patients)
the combination of an ADP-receptor antagonist plus* Correspondence: hernanemilio.polofriz@aovimercate.org
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creativecommons.org/publicdomain/zero/1.0/aspirin based on evidence apparently not in favor of this
choice [8, 9]. However, CHANCE trial showed that ther-
apy with clopidogrel plus aspirin initiated early after
ischemic stroke or transient ischemic attach (TIA) may
further reduce recurrent stroke and major vascular
events compared to aspirin monotherapy [10, 11]. In-
deed, dual antiplatelet therapy associates with an in-
creased risk of bleeding. Therefore, the short-term
benefits and harms of dual antiplatelet therapy observed
in patients with ACS, those undergoing PCI, and those
with ischemic stroke or TIA, are not directly applicable
to long-term therapy and treatment duration is still a
controversial issue.
Thus, research is currently trying to determine which
is the optimal duration of dual antiplatelet therapy in
the setting where it showed a favorable clinical impact.
However these efforts of the scientific community
should not conceal another major issue related to anti-
platelet therapy. That is, the choice of the more appro-
priate antiplatelet monotherapy after the dual treatment
phase. The Global Leaders study conducted with ticagre-
lor, clopidogrel and aspirin after a stent procedure willarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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NCT01813435).
In the meantime the analysis of available evidence may
help to better understand it.
Review
Dual and mono antiplatelet therapy after TIA and
ischemic stroke
In 1996, the CAPRIE trial [12] showed that clopidogrel was
marginally but significantly better than aspirin in patients
with recent ischemic stroke, recent myocardial infarction
(MI), or symptomatic PAD, reducing the relative risk for
the primary endpoint (ischaemic stroke, MI, or vascular
death) by 8.7 % versus aspirin. For the subgroup of patients
with ischemic stroke the relative risk reduction was 7.3 %
(not significant) even though the study was not designed to
specifically address this subgroup of patients. Afterwards,
other randomized controlled trials in patients with coron-
ary manifestations of atherothrombosis were showing the
sustained benefit of clopidogrel on top of standard treat-
ment including aspirin, with an acceptable increase in the
risk of major bleeding complications [13, 14]. Therefore,
the MATCH (Management of ATherothrombosis with Clo-
pidogrel in High-risk patients) study was performed, with
the aim to find out whether aspirin added to clopidogrel as
compared to clopidogrel alone would further reduce the
risk of recurrent ischaemic vascular events in high-risk pa-
tients after TIA or ischaemic stroke [15]. Conclusion was
that although mortality was the same in both groups and
no significant increase in fatal bleeding was recorded,
addition of aspirin to clopidogrel resulted in a significantly
higher bleeding rate that offset the beneficial effect. Adding
aspirin to clopidogrel provided no further benefit, while in-
creasing the harm. However, in the MATCH trial less than
20 % of patients were enrolled within 7 days from stroke
onset, indicating that the trial largely missed the period
when the risk is high and the treatment effect would be
greatest. Moreover, more than 50 % of the patients had an
etiologic mechanism of small-vessel occlusion, which asso-
ciates to major bleeding, decreasing the benefit of clopido-
grel and aspirin dual therapy. Furthermore, a cause of
major or life-threatening bleeding that was increased by
adding aspirin to clopidogrel was gastrointestinal bleeding,
probably indicating the known deleterious effect of aspirin
on the gastrointestinal mucosa [16]. Interestingly enough,
MATCH study results were most considered evidence
against dual therapy (or failure to demonstrate the benefits)
instead of hypotheses generating data on a small but defin-
itely superior benefit of clopidogrel over aspirin as mono-
therapy for stroke. On the contrary, some authors have
questioned on what pushed clinical neurologists from 507
centers in 28 countries participating in the study MATCH
to accept the experimental trial design which provided for
clopidogrel the role of reference therapy in place ofasp2irin. It’ easy to answer this question by recalling that in
those years was emerging that the benefit of aspirin mono-
therapy for secondary prevention in patients with ischemic
stroke or TIA was much less than expected for antiplatelet
therapy as a whole [17]. These data, together with those of
Hankey et al. in his Cochrane review published roughly at
the same time on the modestly but significantly better effi-
cacy of ADP-receptor antagonists as compared with aspirin
in stroke patients [18] constituted a valid reason for all
those neurologist involved in MATCH to try to offer their
patients with stroke something more effective than aspirin
monotherapy.
In 2013, Wang and colleagues reported the results of the
Clopidogrel in High- Risk Patients with Acute Non disab-
ling Cerebrovascular Events (CHANCE) trial [10, 11] which
enrolled 5170 patients with acute minor ischemic stroke or
TIA at high risk for recurrence and, unlike MATCH study,
within 24 h of symptom onset. The addition of clopidogrel
to aspirin in comparison to aspirin alone reduced the rela-
tive risk of recurrent stroke at 90 days by 32 % (8.2 % vs.
11.7 %; hazard ratio, 0.68; 95 % CI, 0.57 to 0.81) with no dif-
ference between the group that received both groups in the
incidence of moderate or severe hemorrhage (0.3 % in each
group; P = 0.73) or hemorrhagic stroke (0.3 % in each
group; P = 0.98). The study demonstrated a substantial
treatment effect with a number-needed-to-treat of 29 for
preventing one recurrent stroke. That is, treating 29 pa-
tients for 90 days with clopidogrel plus aspirin for the first
21 days, followed by clopidogrel alone from day 22 to day
90, prevented one stroke, as compared with aspirin alone.
Is noticeable that most of the absolute benefit of clopidogrel
plus aspirin is obtained within the first few days after the
ischemic event. The strategy adopted in the CHANCE
study to employ dual antiplatelet therapy for less than a
month and then switch to a single agent is proof of how
the lesson of MATCH has been carefully read thus avoiding
to pay a too high tribute in terms of intracranial
hemorrhage since in MATCH intracranial hemorrhages
were becoming significantly more frequent in the group of
combined therapy after the first quarter [19, 20]. The bene-
fit shown by clopidogrel monotherapy compared with
aspirin in the days between 22 and 90 once again under-
lines, in an unbiased reading of CHANCE, the issue already
emerged in the MATCH of clopidogrel as better candidate
for antiplatelet monotherapy after the dual phase, Fig. 1,
and the PROFESS findings still in patients with ischemic
stroke are consistent with this evidence [21].
Dual and mono antiplatelet therapy after PCI
With regard to antiplatelet therapy following PCI, the use
of dual therapy is critically important for the prevention of
coronary stent thrombosis, and this therapy is currently
recommended for 6 to 12 months after implantation of a
drug-eluting stent (DES) [22, 23]. However, the optimal
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Fig. 1 Risk of stroke during different phases (first 21 days, from 22nd to 60th day, from 61st to 90th day) of the CHANCE study [10, 11] follow-up
period. Overall benefit in favour of aspirin-clopidogrel: hazard ratio, 0.68 (95 % CI, 0.57–0.81) P < 0.001
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30-month duration of therapy with aspirin plus an ADP-
receptor antagonist would be superior to a 12-month dur-
ation in patients undergoing PCI, DAPT trial was carried
out and results recently published by Mauri et al. [24]. All
patients received aspirin with 5020 patients randomized to
prolonged DAPT and 4941 to placebo. Approximately two
thirds of the patients received clopidogrel, whereas the rest
received prasugrel. The primary endpoint of major adverse
cardiac and cerebrovascular events was significantly lower
in the continued DAPT arm compared with placebo (4.3 %
vs. 5.9 %, hazard ratio 0.71, 95 % confidence interval 0.59–
0.85, p < 0.001). There were reductions in all MI (2.1 % vs.
4.1 %, p < 0.001) and stent thrombosis (0.4 % vs. 1.4 %,
p < 0.001), but all-cause mortality was higher (2.0 % vs.
1.5 %, p = 0.05), driven mostly by an increase in non-
cardiovascular deaths (1 % vs. 0.5 %, p = 0.002), including
cancer-related death (0.62 % vs. 0.28 %, p = 0.02) and
bleeding-related death (0.22 % vs. 0.06 %, p = 0.06). GUSTO
moderate and severe bleeding was also higher with DAPT
(2.5 % vs. 1.6 %, p = 0.001). The results of the DAPT trial
indicate that prolonged duration of DAPT up to 30 months
following index PCI with a DES results in lower stent
thrombosis and recurrent MIs compared with a 12-month
duration of DAPT, although bleeding and all-cause mortal-
ity were higher with prolonged therapy. The excess in mor-
tality is concerning, but appears to be a combination of
cancer-related and bleeding-related mortality. However, an
important finding of the study risks of going unnoticed. In
the mentioned trial, the interruption of ADP-receptor an-
tagonists therapy both in the group of early discontinuation
and in those receiving extended dual therapy was followedin the next quarter by an important increase of stent
thrombosis and MI, suggesting that an ADP-receptor an-
tagonist instead of aspirin might be the best choice as
monotherapy after dual phase antiplatelet treatment, Fig. 2.
Yet is easy to refer to the evidence which made possible
[24, 25] the large-scale use of coronary stents in clinical
practice thanks to the addiction of ADP-receptor antago-
nists to aspirin which alone had failed in preventing stent
occlusion. The question that arises from DAPT and a num-
ber of previous studies [26] is why antiplatelet monotherapy
after the dual phase should only be based on aspirin? What
is the evidence supporting that patients after a period of
dual antiplatelet therapy for having received a coronary
stent must return to antiplatelet monotherapy with aspirin?
Instead, in these patients it may make sense to think about
the use of an ADP-receptor antagonist rather than aspirin
as monotherapy.Dual and mono antiplatelet therapy in patients with PAD
In contrast to coronary artery disease and ischemic
stroke, there have not been trials with sufficient power
to estimate precisely the preventive effects of antiplatelet
drugs in patients with PAD. A meta-analysis compared
the efficacy of antiplatelet therapy in approximately
135,000 high-risk patients with vascular diseases, includ-
ing 9214 patients with lower extremity PAD. Among
those patients with PAD treated with antiplatelet therapy
there was a 23 % relative risk reduction (p < 0.004) of ad-
verse cardiovascular events, like MI, stroke, or vascular
death. However, only one third of the patients were
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Fig 2 DAPT study [24]: risk of stent thrombosis in patients treated for 12 and 30 months during the 3 months after discontinuation of
thienopyridine treatment
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et al. [28] on 5269 subjects with PAD investigated the effi-
cacy of aspirin alone or the combination of aspirin and di-
pyridamole. In the subset of 3019 participants taking
aspirin alone vs control, aspirin was associated with a non-
significant reduction in cardiovascular events (RR, 0.75;
95 % CI, 0.48–1.18). On the other hand, in the subgroup of
patients with PAD in the CAPRIE study, a reduction of car-
diovascular events was observed in clopidogrel-treated pa-
tients compared to those who received aspirin. The
reduction, deriving from a prespecified analysis and result-
ing from a stratified randomization for the clinical condi-
tion of PAD, was 22.8 % and was consistent with the overall
direction of the study results.
In aggregate these evidences are unable to state what
is the best option for the cardiovascular prevention in
PAD patients but perhaps a preference could come for
clopidogrel. However, in spite of scanty and inconclu-
sive data on the efficacy of aspirin in cardiovascular
prevention in PAD patients aspirin remains the most
used drug for management of these patients. Yet, the
American College of Chest Physicians (ACCP) guide-
lines recommend aspirin (75–100 mg/day) or clopido-
grel (75 mg/day) for asymptomatic PAD patients
(including patients with peripheral arterial bypass sur-
gery or percutaneous transluminal angioplasty) as
equivalent drugs and without limitation of clopidogrel
use (Grade 1A) [8] and the 2013 guidelines on the
management of patients with PAD by the American
College of Cardiology Foundation/American Heart As-
sociation recommend Aspirin, typically in daily doses
of 75 to 325 mg, as safe and effective antiplatelet ther-
apy to reduce the risk of MI, stroke, or vascular deathin individuals with symptomatic atherosclerotic lower
extremity PAD and clopidogrel (75 mg per day) as a
safe and effective alternative, with the same level of evi-
dence than aspirin [9].Conclusions
Evidence on the absolute benefits of dual antiplatelet
therapy early after ACS, and PCI and also after ischemic
stroke is clear. However focusing on optimal duration of
dual therapy should not distract the scientific commu-
nity from the very important issue of the choice of the
more appropriate antiplatelet monotherapy after the
dual treatment phase, or as monotherapy in PAD pa-
tients. If a blinded experiment would prove that the
combination of drugs A + B is not more effective than
just drug A but causes more adverse reactions, everyone
would agree with the futility of drug B. What emerged
from a study considered almost heretical as the MATCH
is that but the use of aspirin–in that study the drug
B–has never been discussed as it should have been.
Aspirin, as the oldest antiplatelet drug, seems to be ac-
cepted as the only option for the management of these
patients, in spite of a lack of evidence surprisingly not
highlighted by key opinion leaders and experts.
Questions as why antiplatelet monotherapy after the
dual phase should only be based on aspirin or whether
use of ADP-receptor antagonists rather than aspirin may
be proposed as monotherapy especially now that clopi-
dogrel is available as a generic drug, seems not only have
no answer but also not place in the current specialists’
analysis. As if a dogmatic approach were prevalent. Per-
haps the time for an open debate on these topics is ripe.
Polo Friz et al. Thrombosis Journal  (2015) 13:28 Page 5 of 5Abbreviations
ADP: Adenosine diphosphate; CAD: Coronary artery disease; ACS: Acute
coronary syndrome; PCI: Percutaneous coronary intervention; PAD: Peripheral
arterial disease; TIA: Transient ischemic attach; MI: Myocardial infarction;
DES: Drug-eluting stent.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HPF, MM and CC equally contributed in the conception and the design of
the article. CC has given final approval of the version to be submitted. All
authors read and approved the final manuscript.
Received: 29 January 2015 Accepted: 4 June 2015
References
1. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al.
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur
Heart J. 2011;32(23):2922–32. doi:10.1093/eurheartj/ehr373. Epub 2011 Oct 20.
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of
clopidogrel in addition to aspirin in patients with acute coronary syndromes
without ST-segment elevation. N Engl J Med. 2001;345:494–502.
3. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of
clopidogrel to aspirin in 45,852 patients with acute myocardial infarction:
randomised placebo-controlled trial. Lancet. 2005;366:1607–21.
4. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G,
Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy
for myocardial infarction with ST-segment elevation. N Engl J Med.
2005;352:1179–89.
5. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al.
Effects of pretreatment with clopidogrel and aspirin followed by long-term
therapy in patients undergoing percutaneous coronary intervention: the
PCI-CURE study. Lancet. 2001;358:527–33.
6. Steinhubl SR, Berger PB, Mann 3rd JT, Fry ET, DeLago A, Wilmer C, et al. Early
and sustained dual oral antiplatelet therapy following percutaneous coronary
intervention: a randomized controlled trial. JAMA. 2002;288:2411–20.
7. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G,
Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous
coronary intervention in patients with ST-elevation myocardial infarction
treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294:1224–32.
8. Alonso-Coello P, Bellmunt S, McGorrian C, Anand SS, Guzman R, Criqui MH,
et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic
Therapy and Prevention of Thrombosis, 9th ed: American College of Chest
Physicians EvidenceBased Clinical Practice Guidelines. Chest.
2012;141:e669S–90.
9. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss L, et al. American
College of Cardiology Foundation Task Force; American Heart Association Task
Force. Management of patients with peripheral artery disease (compilation of
2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the
American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(14):1555–70. doi:10.1016/
j.jacc.2013.01.004. Epub 2013 Mar 6.
10. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with
aspirin in acute minor stroke or transient ischemic attack. N Engl J Med.
2013;369:11–9.
11. Wang Y, Johnston SC, Wang YO. Clopidogrel with aspirin in minor stroke or
transient ischemic attack. N Engl J Med. 2013;369(14):1376–7. doi:10.1056/
NEJMc1309713.
12. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel
versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet.
1996;348:1329–39.
13. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial
Investigators. Effects of clopidogrel in addition to aspirin in patients with
acute coronary syndromes without ST-segment elevation. N Engl J Med.
2001;345:494–502.
14. Steinhubl S, Berger P. What is the role for improved long-term antiplatelet
therapy after percutaneous coronary intervention? Am Heart J.
2003;145(6):971–8.15. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al.
MATCH investigators. Aspirin and clopidogrel compared with clopidogrel
alone after recent ischaemic stroke or transient ischaemic attack in high-risk
patients (MATCH): randomised, double-blind, placebo-controlled trial.
Lancet. 2004;364(9431):331–7.
16. Fork FT, Lafolie P, Tóth E, Lindgärde F. Gastroduodenal tolerance of 75 mg
clopidogrel versus 325 mg aspirin in healthy volunteers. Scand J Gastroenterol.
2000;35:464–9.
17. van Gijn J, Algra A. Aspirin and stroke prevention. Thromb Res.
2003;110(5–6):349–53.
18. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives
(ticlopidine, clopidogrel) versus aspirin for preventing stroke and other
serious vascular events in high vascular risk patients. Cochrane Database
Syst Rev. 2000;2:CD001246.
19. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al.
Clopidogrel and aspirin versus aspirin alone for the prevention of
atherothrombotic events. N Engl J Med. 2006;354:1706–17.
20. The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients
with recent lacunar stroke. N Engl J Med. 2012;367:817–25.
21. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al.
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent
stroke. N Engl J Med. 2008;359(12):1238–51.
22. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report
of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines and the Society for
Cardiovascular Angiography and Interventions. Circulation.
2011;124(23):e574–651.
23. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/
EACTS Guidelines on myocardial revascularization: The Task Force on
Myocardial Revascularization of the European Society of Cardiology (ESC)
and the European Association for Cardio-Thoracic Surgery (EACTS) developed
with the special contribution of the European Association of Percutaneous
Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.
24. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al.
DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy
after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66. doi:10.1056/
NEJMoa1409312.
25. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M,
et al. A randomized comparison of antiplatelet and anticoagulant therapy
after the placement of coronary-artery stents. N Engl J Med.
1996;334(17):1084–9.
26. Gaglia Jr MA, Waksman R. Systematic review of thienopyridine
discontinuation and its impact upon clinical outcomes. Eur Heart J.
2011;32(19):2358–64. doi:10.1093/eurheartj/ehr141. Epub 2011 Jul 30.
27. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised
trials of antiplatelet therapy for prevention of death, myocardial infarction, and
stroke in high risk patients. BMJ. 2002;324:71–86.
28. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of
cardiovascular events in patients with peripheral artery disease: a meta-analysis
of randomized trials. JAMA. 2009;301:1909–19.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
